Tumor vaccination for high-grade glioma
Corresponding Author
Paul G. Schlegel MD
Department of Pediatric Hemato-Oncology and Neurooncology, University Children's Hospital, University of Wuerzburg, Wuerzburg, Germany
Professor of Pediatrics, Chief Pediatric Hemato-Oncology and Neurooncology Program, University Children's Hospital, University of Wuerzburg, Wuerzburg D-97080, Germany.===Search for more papers by this authorMatthias Eyrich MD
Department of Pediatric Hemato-Oncology and Neurooncology, University Children's Hospital, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorChristof Kramm MD
Department of Pediatric Hemato-Oncology and Neurooncology, University Children's Hospital, University of Halle, Halle, Germany
Search for more papers by this authorStefaan van Gool MD, PhD
Department of Pediatric Hemato-Oncology and Neurooncology, Laboratory of Experimental Immunology, Laboratory of Cell and Gene Therapy, University of Leuven, Leuven, Belgium
Search for more papers by this authorCorresponding Author
Paul G. Schlegel MD
Department of Pediatric Hemato-Oncology and Neurooncology, University Children's Hospital, University of Wuerzburg, Wuerzburg, Germany
Professor of Pediatrics, Chief Pediatric Hemato-Oncology and Neurooncology Program, University Children's Hospital, University of Wuerzburg, Wuerzburg D-97080, Germany.===Search for more papers by this authorMatthias Eyrich MD
Department of Pediatric Hemato-Oncology and Neurooncology, University Children's Hospital, University of Wuerzburg, Wuerzburg, Germany
Search for more papers by this authorChristof Kramm MD
Department of Pediatric Hemato-Oncology and Neurooncology, University Children's Hospital, University of Halle, Halle, Germany
Search for more papers by this authorStefaan van Gool MD, PhD
Department of Pediatric Hemato-Oncology and Neurooncology, Laboratory of Experimental Immunology, Laboratory of Cell and Gene Therapy, University of Leuven, Leuven, Belgium
Search for more papers by this author
REFERENCES
- 1 Forman NK, Donson AM. Tumor vaccination for malignant brain tumors. Pediatr Blood Cancer 2010; 54: 495–496.
- 2 Ardon H, de Vleeschouwer S, van Calenbergh F, et al. Adjuvant dendritic cell-based tumor vaccination for children with malignant brain tumors. Pediatr Blood Cancer 2010; 54: 519–525.
- 3 de Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14: 3098–3104.
- 4 Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641–648.
- 5 Wei J, Barr J, Kong LJ, et al. Glioma-associated cancer initiating cells induce immunosuppression. Clin Cancer Res 2010; 16: 461–473.
- 6 Maes W, Rosas GG, Verbinnen B, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro-Oncology 2009; 11: 529–542.
- 7 Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68: 5955–5964.
- 8 Bonehill A, van Nuffel AM, Corthals J, et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009; 15: 3366–3375.
